Neimeth International Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Neimeth International Pharmaceuticals's earnings have been declining at an average annual rate of -79%, while the Pharmaceuticals industry saw earnings growing at 6.4% annually. Revenues have been declining at an average rate of 0.1% per year.
Key information
-79.0%
Earnings growth rate
-68.8%
EPS growth rate
Pharmaceuticals Industry Growth | 21.6% |
Revenue growth rate | -0.1% |
Return on equity | -195.0% |
Net Margin | -129.7% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Neimeth International Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 2,210 | -2,865 | 1,636 | 0 |
30 Sep 23 | 1,919 | -1,097 | 1,389 | 0 |
30 Jun 23 | 2,242 | -953 | 1,410 | 0 |
31 Mar 23 | 2,595 | -615 | 1,152 | 0 |
31 Dec 22 | 2,919 | -325 | 1,204 | 0 |
30 Sep 22 | 2,703 | -110 | 1,125 | 0 |
30 Jun 22 | 2,882 | 52 | 1,174 | 0 |
31 Mar 22 | 2,750 | 33 | 1,178 | 0 |
31 Dec 21 | 2,844 | 140 | 1,133 | 0 |
30 Sep 21 | 3,047 | 271 | 1,074 | 0 |
30 Jun 21 | 2,824 | 60 | 1,005 | 0 |
31 Mar 21 | 2,956 | 184 | 1,001 | 0 |
31 Dec 20 | 2,627 | -49 | 984 | 0 |
30 Sep 20 | 2,839 | 212 | 939 | 0 |
30 Jun 20 | 2,967 | 427 | 893 | 0 |
31 Mar 20 | 2,560 | 271 | 780 | 0 |
31 Dec 19 | 2,751 | 442 | 771 | 0 |
30 Sep 19 | 2,371 | 220 | 745 | 0 |
30 Jun 19 | 2,345 | 118 | 803 | 0 |
31 Mar 19 | 2,368 | 124 | 899 | 0 |
31 Dec 18 | 2,102 | -5 | 903 | 0 |
30 Sep 18 | 2,269 | 148 | 897 | 0 |
30 Jun 18 | 1,952 | -91 | 856 | 0 |
31 Mar 18 | 1,810 | -187 | 872 | 0 |
31 Dec 17 | 1,791 | -150 | 871 | 0 |
30 Sep 17 | 1,534 | -411 | 958 | 0 |
30 Jun 17 | 1,718 | -311 | 970 | 0 |
31 Mar 17 | 1,816 | -231 | 958 | 0 |
31 Dec 16 | 1,743 | -235 | 913 | 0 |
30 Sep 16 | 2,002 | 65 | 839 | 0 |
30 Jun 16 | 1,664 | -162 | 897 | 0 |
31 Mar 16 | 1,808 | -54 | 928 | 0 |
31 Dec 15 | 1,588 | -216 | 923 | 0 |
30 Sep 15 | 1,461 | -336 | 889 | 0 |
30 Jun 15 | 1,313 | -297 | 876 | 0 |
31 Mar 15 | 1,261 | -397 | 856 | 0 |
31 Dec 14 | 1,429 | -372 | 907 | 0 |
30 Sep 14 | 1,628 | -229 | 891 | 0 |
30 Jun 14 | 2,000 | 116 | 1,462 | 0 |
31 Mar 14 | 2,105 | 86 | 904 | 0 |
31 Dec 13 | 2,150 | 178 | 882 | 0 |
30 Sep 13 | 2,017 | 131 | 873 | 0 |
30 Jun 13 | 1,829 | -39 | 0 | 0 |
Quality Earnings: NEIMETH is currently unprofitable.
Growing Profit Margin: NEIMETH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEIMETH is unprofitable, and losses have increased over the past 5 years at a rate of 79% per year.
Accelerating Growth: Unable to compare NEIMETH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEIMETH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.4%).
Return on Equity
High ROE: NEIMETH has a negative Return on Equity (-195.01%), as it is currently unprofitable.